Skip to content

Clinical study for modified Suanzaoren decoction in the treatment of post-stroke cognitive impairment

The study for modified Suanzaoren decoction in the treatment of post-stroke cognitive impairment with insomnia and its impact on the HPA axis and cerebral blood flow

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023297
Enrollment
Unknown
Registered
2019-05-21
Start date
2019-06-01
Completion date
Unknown
Last updated
2019-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post-stroke cognitive disorder combined with insomnia

Interventions

Experiment Group:Basic therapy + Cognitive rehabilitation training+ Modified Suanzaoren Decoction
Control group 1: Basic therapy + Cognitive rehabilitation training + Estazolam
Control group 2: Basic therapy + Cognitive rehabilitation training

Sponsors

Tongde Hospital of Zhejiang Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Cerebral hemorrhage cerebral infarction diagnosed by CT or MRI and the Live-Yin deficiency syndrome is diagnosed. 2. Mild cognitive disorder is diagnosed according to Expert consensus on management of poststroke cognitive impairment 2017and the insomnia is diagnosed according to Guidelines for the diagnosis and treatment of insomnia in Chinese adults. 3. Paticipants agree to sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Stroke with disturbance of consciousness or disease that too serious to cooperate with the relevant examination 2. Serious mental disorder or have a history of mental illness. 3. Participants with severe aphasia, inability to write, sever cognitive decline that are hardly to cooperative. 4. Sever cardiopulmonary failure or other sever physical disease that cannot comply with treatment. 5.Insomnia or cognitive disorder (such as alzheimer's disease) before this onset of stroke. 6. Participants are taking drugs for the central nervous system, such as benzodiazepines, antidepressants and antipsychotics. 7. Participants are or had been in other clinical trials that may affect the outcome of this study

Design outcomes

Primary

MeasureTime frame
Cognitive evaluation;Sleep quality evaluation;

Secondary

MeasureTime frame
activity of daily living (ADL);cerebral blood flow;

Countries

China

Contacts

Public ContactZhu Mingjin

Tongde Hospital of Zhejing Province

zhumingjin@163.com+86 15988116812

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026